Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Soligenix Inc (OTCQB:SNGX)

3.10
Real-Time Quote
As of 11:38am ET
 +0.08 / +2.65%
Today’s Change
2.92
Today|||52-Week Range
14.40
-72.57%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$11.4M

Company Description

Soligenix, Inc. is a clinical stage biopharmaceutical company. It is focused on developing products to treat serious gastrointestinal diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics. The company operates through BioTherapeutics and Vaccines/BioDefense segments. The BioTherapeutics segment intends to develop oral beclomethasone dipropionate indications such as pediatric crohn's disease and acute radiation enteritis. The Vaccines/BioDefense segment includes active development programs for RiVax, its ricin toxin vaccine, and VeloThrax, its anthrax vaccine, and OrbeShield, its gastrointestinal acute radiation syndrome therapeutic. Soligenix was founded in 1987 and is headquartered Princeton, NJ.

Contact Information

Soligenix, Inc.
29 Emmons Drive
Princeton New Jersey 08540-5919
P:(609) 538-8200
Investor Relations:

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Christopher J. SchaberChairman, President & Chief Executive Officer
Karen R. KrumeichChief Financial Officer & Senior Vice President
Oreola DoniniChief Scientific Officer & Senior Vice President
Richard C. StraubeChief Medical Officer & Senior Vice President
Rasappa ArumughamVice President-Biopharmaceutical Development